{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:41:54Z","timestamp":1764171714387,"version":"3.46.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12085-w","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:34:40Z","timestamp":1764171280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The safety profile of trimethoprim-sulfamethoxazole regarding concomitant other drugs: a comparative analysis of adverse effects in a tertiary level adult intensive care unit"],"prefix":"10.1186","volume":"25","author":[{"given":"Mefk\u00fcre","family":"Durmu\u015f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davut","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sena","family":"Usta\u00f6mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sena","family":"G\u00fczel Karahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet O\u011fuzhan","family":"K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehtap","family":"Pehlivanlar K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"12085_CR1","doi-asserted-by":"publisher","unstructured":"Lawson DH, Paice BJ. Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis. 1982;429\u201333. https:\/\/doi.org\/10.1093\/clinids\/4.2.429.","DOI":"10.1093\/clinids\/4.2.429"},{"key":"12085_CR2","doi-asserted-by":"publisher","unstructured":"Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1999;74(7):730\u20134. https:\/\/doi.org\/10.4065\/74.7.730.","DOI":"10.4065\/74.7.730"},{"issue":"5","key":"12085_CR3","doi-asserted-by":"publisher","first-page":"e0285541","DOI":"10.1371\/journal.pone.0285541","volume":"18","author":"TB Jacobo-Vargas","year":"2023","unstructured":"Jacobo-Vargas TB, B\u00e1ez-Salda\u00f1a R, Cruz-Hervert LP, Fortoul TI, Ahumada-Topete VH, et al. Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: A cohort study. PLoS ONE. 2023;18(5):e0285541. https:\/\/doi.org\/10.1371\/journal.pone.0285541.","journal-title":"PLoS ONE"},{"issue":"2","key":"12085_CR4","first-page":"86","volume":"17","author":"MA Kielhofner","year":"1990","unstructured":"Kielhofner MA. Trimethoprim-sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions. Tex Heart Inst J. 1990;17(2):86\u201393.","journal-title":"Tex Heart Inst J"},{"issue":"1","key":"12085_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/mr\/roae059","volume":"35","author":"K Hiramoto","year":"2024","unstructured":"Hiramoto K, Akiyama M, Kaneko Y. Risk factors for adverse drug reactions to sulfamethoxazole-trimethoprim prophylaxis in patients with rheumatic and musculoskeletal diseases. Mod Rheumatol. 2024;35(1):94\u2013101. https:\/\/doi.org\/10.1093\/mr\/roae059.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"12085_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jcma.2016.01.007","volume":"79","author":"HM Chang","year":"2016","unstructured":"Chang HM, Tsai HC, Lee SS, Kunin C, Lin PC, et al. High daily doses of trimethoprim\/sulfamethoxazole are an independent risk factor for adverse reactions in patients with Pneumocystis pneumonia and AIDS. J Chin Med Association. 2016;79(6):314\u20139. https:\/\/doi.org\/10.1016\/j.jcma.2016.01.007.","journal-title":"J Chin Med Association"},{"issue":"5","key":"12085_CR7","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/clinids\/24.5.936","volume":"24","author":"J Veenstra","year":"1997","unstructured":"Veenstra J, Veugelers PJ, Keet IP, van der Ven AJ, Miedema F, et al. Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Clin Infect Dis. 1997;24(5):936\u201341. https:\/\/doi.org\/10.1093\/clinids\/24.5.936.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"12085_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/archinternmed.2010.142","volume":"170","author":"T Antoniou","year":"2010","unstructured":"Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, et al. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med. 2010;170(12):1045\u20139. https:\/\/doi.org\/10.1001\/archinternmed.2010.142.","journal-title":"Arch Intern Med"},{"issue":"4","key":"12085_CR9","doi-asserted-by":"publisher","first-page":"E138","DOI":"10.1503\/cmaj.140816","volume":"187","author":"T Antoniou","year":"2015","unstructured":"Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ. 2015;187(4):E138\u201343. https:\/\/doi.org\/10.1503\/cmaj.140816.","journal-title":"CMAJ"},{"key":"12085_CR10","doi-asserted-by":"publisher","first-page":"107283","DOI":"10.1016\/j.ijid.2024.107283","volume":"150","author":"GE Martin","year":"2025","unstructured":"Martin GE, Bramwell J, Gadil E, Woerle C, Ewin T, et al. Adverse reactions to trimethoprim\/sulfamethoxazole for melioidosis eradication therapy: an evaluation of frequency and risk factors. Int J Infect Dis. 2025;150:107283. https:\/\/doi.org\/10.1016\/j.ijid.2024.107283.","journal-title":"Int J Infect Dis"},{"key":"12085_CR11","doi-asserted-by":"publisher","first-page":"h2219","DOI":"10.1136\/bmj.h2219","volume":"350","author":"M Paul","year":"2015","unstructured":"Paul M, Bishara J, Yahav D, Goldberg E, Neuberger A, et al. Trimethoprim-sulfamethoxazole versus Vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ. 2015;350:h2219. https:\/\/doi.org\/10.1136\/bmj.h2219.","journal-title":"BMJ"},{"issue":"2","key":"12085_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2174\/1574886311308020004","volume":"8","author":"AT Nguyen","year":"2013","unstructured":"Nguyen AT, Gentry CA, Furrh RZ. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting. Curr Drug Saf. 2013;8(2):114\u20139. https:\/\/doi.org\/10.2174\/1574886311308020004.","journal-title":"Curr Drug Saf"},{"issue":"1","key":"12085_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.37678\/dcybd.2021.2534","volume":"12","author":"T Mengi","year":"2021","unstructured":"Mengi T, Ozkok H, Comert B. Evaluation of hyperkalemia associated with Trimethoprim-Sulfamethoxazole in the intensive care unit. J Crit Intensive Care. 2021;12(1):27. https:\/\/doi.org\/10.37678\/dcybd.2021.2534.","journal-title":"J Crit Intensive Care"},{"issue":"8","key":"12085_CR14","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3390\/antibiotics11081138","volume":"11","author":"H Seo","year":"2022","unstructured":"Seo H, Kim E. Incidence and determinants of Piperacillin\/Tazobactam-Associated hypokalemia: A retrospective study. Antibiot (Basel). 2022;11(8):1138. https:\/\/doi.org\/10.3390\/antibiotics11081138.","journal-title":"Antibiot (Basel)"},{"issue":"2","key":"12085_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/antibiotics12020240","volume":"12","author":"H Seo","year":"2023","unstructured":"Seo H, Kim E. Electrolyte disorders associated with Piperacillin\/Tazobactam: A pharmacovigilance study using the FAERS database. Antibiot (Basel). 2023;12(2):240. https:\/\/doi.org\/10.3390\/antibiotics12020240.","journal-title":"Antibiot (Basel)"},{"issue":"16","key":"12085_CR16","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1503\/cmaj.111152","volume":"183","author":"JM Ho","year":"2011","unstructured":"Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ. 2011;183(16):1851\u20138. https:\/\/doi.org\/10.1503\/cmaj.111152.","journal-title":"CMAJ"},{"issue":"11","key":"12085_CR17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.jiac.2021.07.011","volume":"27","author":"T Hirai","year":"2021","unstructured":"Hirai T, Yamaga R, Ishikawa Y, Hanada K, Iwamoto T, et al. Effect of high-dose sulfamethoxazole\/trimethoprim and glucocorticoid use on hyperkalemic event: A retrospective observational study. J Infect Chemother. 2021;27(11):1607\u201313. https:\/\/doi.org\/10.1016\/j.jiac.2021.07.011.","journal-title":"J Infect Chemother"},{"issue":"4","key":"12085_CR18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jac\/dkp280","volume":"64","author":"S Mohan","year":"2009","unstructured":"Mohan S, Jaitly M, Pogue VA, Cheng JT. Influence of concomitant prednisolone on trimethoprim-associated hyperkalaemia. J Antimicrob Chemother. 2009;64(4):850\u20132. https:\/\/doi.org\/10.1093\/jac\/dkp280.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"12085_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s00134-002-1244-3","volume":"28","author":"KH Polderman","year":"2002","unstructured":"Polderman KH, Girbes AR. Piperacillin-induced magnesium and potassium loss in intensive care unit patients. Intensive Care Med. 2002;28(4):520\u20132. https:\/\/doi.org\/10.1007\/s00134-002-1244-3.","journal-title":"Intensive Care Med"},{"key":"12085_CR20","unstructured":"Zhou Y, Jia P, Yang X, Huang Y, Fang Y, et al. The real-world safety profile of piperacillin-tazobactam: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS). Available at SSRN 4971492."},{"key":"12085_CR21","unstructured":"Zheng DaWu ZD, Luo YongXiang LY, Jiang Kuan JK, Ma YuanLiang MY, Yao QinJiang YQ. Clinical efficacy of piperacillin\/tazobactam combined with probiotics in treatment of cirrhosis complicated with spontaneous bacterial peritonitis and its effect on liver function and inflammatory cytokines. Chin J Nosocomiology. 2018;28(23):3544\u20138."},{"issue":"1","key":"12085_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cld.2010.09.013","volume":"15","author":"MM Singh","year":"2011","unstructured":"Singh MM, Pockros PJ. Hematologic and oncologic diseases and the liver. Clin Liver Disease. 2011;15(1):69\u201387. https:\/\/doi.org\/10.1016\/j.cld.2010.09.013.","journal-title":"Clin Liver Disease"},{"key":"12085_CR23","unstructured":"Donald M, Arnold AC. Drug-induced immune thrombocytopenia. Accessed 15 Dec 2024. https:\/\/www.uptodate.com\/contents\/drug-induced-immune-thrombocytopenia"},{"issue":"3","key":"12085_CR24","doi-asserted-by":"publisher","first-page":"32256","DOI":"10.32598\/ijmtfm.v10i3.32256","volume":"10","author":"H Talaie","year":"2020","unstructured":"Talaie H, Hosseini SM, Nazari M, Esfahani MS, Barari B. Risk factors of Hospital-acquired thrombocytopenia in toxicological intensive care unit: thrombocytopenia in toxicological intensive care unit. Int J Med Toxicol Forensic Med. 2020;10(3):32256\u201332256. https:\/\/doi.org\/10.32598\/ijmtfm.v10i3.32256.","journal-title":"Int J Med Toxicol Forensic Med"},{"issue":"1","key":"12085_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12959-024-00641-4","volume":"22","author":"Q Cheng","year":"2024","unstructured":"Cheng Q, Wu Y, Yao Z, Ouyang M, Zou S, et al. Coagulation dysfunction events associated with echinocandins: a real-world study from FDA adverse event reporting system (FAERS) database. Thromb J. 2024;22(1):78. https:\/\/doi.org\/10.1186\/s12959-024-00641-4.","journal-title":"Thromb J"},{"issue":"9","key":"12085_CR26","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00277-022-04907-7","volume":"101","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Batiha GE. Hemolytic anemia in COVID-19. Ann Hematol. 2022;101(9):1887\u201395. https:\/\/doi.org\/10.1007\/s00277-022-04907-7.","journal-title":"Ann Hematol"},{"issue":"5","key":"12085_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/jac\/dks030","volume":"67","author":"TN Fraser","year":"2012","unstructured":"Fraser TN, Avellaneda AA, Graviss EA, Musher DM. Acute kidney injury associated with trimethoprim\/sulfamethoxazole. J Antimicrob Chemother. 2012;67(5):1271\u20137. https:\/\/doi.org\/10.1093\/jac\/dks030.","journal-title":"J Antimicrob Chemother"},{"key":"12085_CR28","doi-asserted-by":"publisher","first-page":"d5228","DOI":"10.1136\/bmj.d5228","volume":"343","author":"T Antoniou","year":"2011","unstructured":"Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ. 2011;343:d5228. https:\/\/doi.org\/10.1136\/bmj.d5228.","journal-title":"BMJ"},{"key":"12085_CR29","doi-asserted-by":"publisher","first-page":"102807","DOI":"10.1016\/j.jiac.2025.102807","volume":"31","author":"H Oishi","year":"2025","unstructured":"Oishi H, Koutake Y, Ebata N, Nagasaki Y, Hashimoto M. Teicoplanin total trough concentration and adverse effects in patients with hypoalbuminemia. J Infect Chemother. 2025;31:102807. https:\/\/doi.org\/10.1016\/j.jiac.2025.102807.","journal-title":"J Infect Chemother"},{"key":"12085_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12877-024-05091-1","volume":"24","author":"T Liu","year":"2024","unstructured":"Liu T, Wu J, Na P, Wu X, Yuan Y, et al. Necessity for higher Teicoplanin doses in older adults: a multicenter prospective observational study in China. BMC Geriatr. 2024;24:487. https:\/\/doi.org\/10.1186\/s12877-024-05091-1.","journal-title":"BMC Geriatr"},{"issue":"1","key":"12085_CR31","first-page":"11","volume":"119","author":"DG Maki","year":"1992","unstructured":"Maki DG, Fox BC, Kuntz J, Sollinger HW, Belzer FO. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine. J Lab Clin Med. 1992;119(1):11\u201324.","journal-title":"J Lab Clin Med"},{"issue":"3","key":"12085_CR32","first-page":"1855","volume":"1856","author":"\u0410L Shtroblya","year":"2021","unstructured":"Shtroblya \u0410L, Drogovoz S\u041c, Shchokina KG, Taran AV, Kalko KO, et al. Features of side effects of sulfamethoxazole\/Trimethoprim combined pharmacotherapy. PharmacologyOnline. 2021;1856(3):1855\u201362.","journal-title":"PharmacologyOnline"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12085-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:34:42Z","timestamp":1764171282000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-12085-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12085"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12085-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures in this study involving human participants complied with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Ethical approval for this descriptive and analytical study involving human participants was obtained from the Karadeniz Technical University Faculty of Medicine Scientific Research Ethics Committee (approval date: 27.05.2024, approval number: 2024\/106). Consent to participate was not applicable because of the retrospective design and anonymous data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1662"}}